Active surveillance is noninferior to BCG induction therapy for invasive relapse-free survival in patients with high-grade T1 bladder cancer with no residual tumor on second TURBT. For patients with ...

POTOMAC data support a year's worth of immuontherapy paired with BCG induction and mainten ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

TAR-200 demonstrated high DFS and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer with papillary-only disease. The phase 2b SunRISe-1 study showed over 80% ...

ImmunityBio to serve as sole U.S. Biologics License Application applicant for the Tokyo strain of BCG and plans to engage with U.S. Food and Drug Administration (FDA) on regulatory pathway to address ...

A noninvasive urinary DNA methylation test demonstrated high sensitivity for detecting high-grade or invasive bladder cancer. A urinary DNA methylation test displayed superior sensitivity for ...

ImmunityBio (IBRX) stock is in focus as the firm licenses U.S. rights to Tokyo-172 BCG for bladder cancer after Phase 3 data ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Urothelial carcinoma is cancer of the urinary system. The urothelium is a kind of epithelial (protective) lining of the urinary system, which includes the urinary tract, bladder, your ureters (the ...

What Is Transurethral Resection of Bladder Tumor (TURBT)? If you have bladder cancer or suspected bladder cancer, your doctor has probably told you that you need a transurethral resection of the ...